Synopsis: Ace investor Vijay Kishanlal Kedia acquired a 3.81% stake in Mahamaya Lifesciences via a ₹12.48 crore block deal, signalling strong confidence in the SME company’s growth prospects and long-term potential.
This Micro-cap Agrochemical stock, engaged in manufacturing and marketing pesticide formulations, including insecticides, fungicides, herbicides, biostimulants, and biofertilizers for domestic and international agrochemical markets, jumped 12.77 percent after Vijay Kedia made a fresh stake of 3.81 percent in the company
With a market capitalization of Rs. 395.43 crores, the share of Mahamaya Lifesciences Limited has reached an intraday high of Rs. 181 per equity share, rising nearly 12.77 percent from its previous day’s close price of Rs. 160.50. Since then, the stock has retreated and is currently trading at Rs. 168.95 per equity share.
Reason Behind the Surge:
Ace investor Vijay Kishanlal Kedia made a notable investment in SME company Mahamaya Lifesciences through a block deal on Tuesday. His firm, Kedia Securities Private Ltd, purchased nearly 8.92 lakh shares of the company at an average price of Rs. 140 per share. This bulk purchase translates into a total transaction value of around Rs. 12.48 crore.
On the other side of the deal, Almondz Global Securities Limited sold about 1.51 lakh shares at a higher price of Rs. 143.64 per share. The transaction highlights continued interest from seasoned investors in select SME stocks and reflects confidence in Mahamaya Lifesciences’ business prospects and long-term growth potential.
Mahamaya Lifesciences Limited had a majority stake held by the promoters at 56.35 percent, foreign institutional investors at 6.39 percent, domestic institutional investors at 4.67 percent, and the public at 32.30 percent in November 2025. Ace investor Vijay Kishanlal Kedia has bought a fresh stake of approximately 3.81 percent of Mahamaya Lifesciences Limited.
Company Overview:
Mahamaya Lifesciences Limited was incorporated in 2002 and is an agrochemical company engaged in manufacturing, registration, and export of crop protection products and bioproducts aimed at improving crop and soil health. The company supports the farming community by providing effective solutions that help enhance agricultural productivity.
The company specializes in manufacturing pesticide formulations and supplying bulk agrochemical products to Indian agrochemical companies as well as multinational corporations. It imports carefully researched molecules, registers them with the Central Insecticides Board, and markets them as technical and value-added formulations.
Mahamaya Lifesciences has invested in global product registrations and operates in international markets such as Egypt, Ethiopia, the UAE, Turkey, Jordan, and the Dominican Republic. Its diverse product portfolio includes bulk formulations, technical products, branded formulations, and export-focused agrochemical solutions.
IPO Details:
Mahamaya Lifesciences Limited came for an Initial Public Offering (IPO) scheduled from November 11 to 13, 2025. The IPO aims to raise approximately Rs. 70.44 crores by a combination of fresh issue of 0.56 crore shares aggregating to Rs. 64.28 crores and offer for sale of 0.05 crore shares aggregating to Rs. 6.16 crores.
This move is part of the company’s strategy to fund the purchase of equipment for the existing formulation plant, capital expenditure for a new technical manufacturing plant, construction of Warehouse Building and Purchase of Machinery, working capital requirements, and general corporate purposes.
Recent Quarter Results:
Coming into financial highlights, Mahamaya Lifesciences Limited’s revenue has increased from Rs. 146 crore in H1 FY25 to Rs. 163 crore in H1 FY26, which has grown by 11.64 percent. The net profit has also grown by 14.29 percent from Rs. 7 crore in H1 FY25 to Rs. 8 crore in H1 FY26.
Mahamaya Lifesciences Limited’s revenue and net profit have grown at a CAGR of 43.15 percent and 63.03 percent, respectively, over the last three years.
In terms of return ratios, the company’s ROCE and ROE stand at 25.9 percent and 34.9 percent, respectively. Mahamaya Lifesciences Limited has an earnings per share (EPS) of Rs. 7.28, and its debt-to-equity ratio is 1.18x.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
